Hoth Therapeutics (NASDAQ:HOTH) Announces Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) released its quarterly earnings data on Friday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07, Zacks reports.

Hoth Therapeutics Trading Up 3.0 %

NASDAQ HOTH traded up $0.03 on Friday, hitting $1.03. 132,124 shares of the stock traded hands, compared to its average volume of 3,413,480. The company has a market capitalization of $7.11 million, a P/E ratio of -0.78 and a beta of 0.84. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80. The stock has a 50-day moving average of $1.14 and a 200 day moving average of $1.01.

Analysts Set New Price Targets

Several equities analysts recently commented on HOTH shares. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.